Iclusig® (Ponatinib) in Clinical Practice for the Treatment of Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia in Belgium

Phase II Front-line Ponatinib in Adult Philadelphia+/BCR-ABL+ Acute Lymphoblastic Leukemia.

NCT01641107 ·Status: COMPLETED ·Phase: PHASE2

Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)

NCT01207440 ·Status: COMPLETED ·Phase: PHASE2

Cardiovascular Assessment of Ponatinib as Third Line Treatment in Chronic Phase Chronic Myeloid Leukemia

NCT04709731 ·Status: UNKNOWN ·Phase: PHASE2

Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase

NCT04070443 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors

NCT03934372 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Expanded Access Program of Ponatinib

NCT01592136 ·Status: APPROVED_FOR_MARKETING

A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia

NCT05304377 ·Status: RECRUITING ·Phase: PHASE1

Phase III Study of Compound Formula Realgar-Indigo Naturalis Plus Imatinib Versus Placebo Plus Imatinib in Adult CML-CP Patients With Ph+

NCT01755325 ·Status: SUSPENDED ·Phase: PHASE3

Long-acting Low Dose Ropeginterferon for Chronic Myeloid Leukemia Treated With Bosutinib From Diagnosis

NCT03831776 ·Status: COMPLETED ·Phase: PHASE2

A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice

NCT03425591 ·Status: COMPLETED

Activity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic Leukemia

NCT03455517 ·Status: COMPLETED ·Phase: PHASE2

Early Access Program (EAP) for Ibrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

NCT02437019 ·Status: APPROVED_FOR_MARKETING

A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy

NCT02717611 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Study To Describe The Real World Use Of Bosutinib In The UK And Netherlands

NCT02546375 ·Status: COMPLETED

Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid Leukemia

NCT04043676 ·Status: UNKNOWN ·Phase: PHASE2

Ibrutinib in Previously Untreated Binet Stage a Chronic Lymphocytic Leukemia with Risk of Disease Progression

NCT02863718 ·Status: COMPLETED ·Phase: PHASE3

A Study Comparing Ponatinib and Nilotinib in Participants With Chronic Myeloid Leukemia

NCT02627677 ·Status: TERMINATED ·Phase: PHASE3

A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic Leukemia

NCT03873493 ·Status: COMPLETED ·Phase: PHASE2

Tolerance and Resistance to Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL

NCT03502876 ·Status: COMPLETED

Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia

NCT01670084 ·Status: WITHDRAWN ·Phase: PHASE2

A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients

NCT03677596 ·Status: COMPLETED ·Phase: PHASE4

Safety of PCI-32765 in Chronic Lymphocytic Leukemia

NCT01105247 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)

NCT03112174 ·Status: COMPLETED ·Phase: PHASE3

A Study of RO5503781 as a Single Agent or in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia

NCT01773408 ·Status: COMPLETED ·Phase: PHASE1

Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL

NCT07301424 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2